Deals Of The Week: Pfizer/Halozyme, Celgene/Sutro Biopharma, Amgen/ImmunoGen
Executive Summary
The week before Christmas proved to be an extraordinarily busy one for biopharmaceutical business development, highlighted by a Pfizer deal to enhance delivery of its biologics, an ALS research consortium led by Biogen Idec and the merger of two European companies, creating vaccine- and antibody-focused Valneva.